Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints.

Winneroski LL, Erickson JA, Green SJ, Lopez JE, Stout SL, Porter WJ, Timm DE, Audia JE, Barberis M, Beck JP, Boggs LN, Borders AR, Boyer RD, Brier RA, Hembre EJ, Hendle J, Garcia-Losada P, Minguez JM, Mathes BM, May PC, Monk SA, Rankovic Z, Shi Y, Watson BM, Yang Z, Mergott DJ.

Bioorg Med Chem. 2020 Jan 1;28(1):115194. doi: 10.1016/j.bmc.2019.115194. Epub 2019 Nov 15.

PMID:
31786008
2.

Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality.

Innes AJ, Woolley P, Szydlo RM, Lozano S, Fernando F, Bansal D, Palanicawandar R, Milojkovic D, May PC, Nadal-Melsio E, Yebra-Fernandez E, Olavarria E, Apperley JF, Pavlů J.

Leukemia. 2020 Feb;34(2):667-670. doi: 10.1038/s41375-019-0572-z. Epub 2019 Sep 2. No abstract available.

3.

National Imaging Trends after Percutaneous Nephrolithotomy.

Dai JC, Ahn JS, Holt SK, May PC, Sorensen MD, Harper JD.

J Urol. 2018 Jul;200(1):147-153. doi: 10.1016/j.juro.2018.01.078. Epub 2018 Feb 1.

PMID:
29409907
4.

The Morbidity of Ureteral Strictures in Patients with Prior Ureteroscopic Stone Surgery: Multi-Institutional Outcomes.

May PC, Hsi RS, Tran H, Stoller ML, Chew BH, Chi T, Usawachintachit M, Duty BD, Gore JL, Harper JD.

J Endourol. 2018 Apr;32(4):309-314. doi: 10.1089/end.2017.0657.

5.

National Imaging Trends after Ureteroscopic or Shock Wave Lithotripsy for Nephrolithiasis.

Ahn JS, Holt SK, May PC, Harper JD.

J Urol. 2018 Feb;199(2):500-507. doi: 10.1016/j.juro.2017.09.079. Epub 2017 Sep 21.

PMID:
28941916
6.

Quantification of Renal Stone Contrast with Ultrasound in Human Subjects.

Cunitz BW, Harper JD, Sorensen MD, Haider YA, Thiel J, May PC, Liu Z, Bailey MR, Dunmire B, Bruce M.

J Endourol. 2017 Nov;31(11):1123-1130. doi: 10.1089/end.2017.0404. Epub 2017 Sep 28.

7.

Detection and Evaluation of Renal Injury in Burst Wave Lithotripsy Using Ultrasound and Magnetic Resonance Imaging.

May PC, Kreider W, Maxwell AD, Wang YN, Cunitz BW, Blomgren PM, Johnson CD, Park JSH, Bailey MR, Lee D, Harper JD, Sorensen MD.

J Endourol. 2017 Aug;31(8):786-792. doi: 10.1089/end.2017.0202. Epub 2017 Jun 16.

8.

Lineage-Specific Genes Are Prominent DNA Damage Hotspots during Leukemic Transformation of B Cell Precursors.

Boulianne B, Robinson ME, May PC, Castellano L, Blighe K, Thomas J, Reid A, Müschen M, Apperley JF, Stebbing J, Feldhahn N.

Cell Rep. 2017 Feb 14;18(7):1687-1698. doi: 10.1016/j.celrep.2017.01.057.

9.

Striking dyserythropoiesis in a myelodysplastic syndrome.

Siow W, May PC, Haji R, Gabriel I, Bain BJ.

Am J Hematol. 2017 Feb;92(2):218. doi: 10.1002/ajh.24549. Epub 2016 Sep 30. No abstract available.

10.

Stone-Mode Ultrasound for Determining Renal Stone Size.

May PC, Haider Y, Dunmire B, Cunitz BW, Thiel J, Liu Z, Bruce M, Bailey MR, Sorensen MD, Harper JD.

J Endourol. 2016 Sep;30(9):958-62. doi: 10.1089/end.2016.0341.

11.

A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans.

Hölttä M, Dean RA, Siemers E, Mawuenyega KG, Sigurdson W, May PC, Holtzman DM, Portelius E, Zetterberg H, Bateman RJ, Blennow K, Gobom J.

Alzheimers Res Ther. 2016 Mar 7;8(1):11. doi: 10.1186/s13195-016-0178-x.

12.

Abnormal villous morphology mimicking a hydatidiform mole associated with paternal trisomy of chromosomes 3,7,8 and unipaternal disomy of chromosome 11.

Sebire NJ, May PC, Kaur B, Seckl MJ, Fisher RA.

Diagn Pathol. 2016 Feb 4;11:20. doi: 10.1186/s13000-016-0471-9.

13.

Ultrasonic propulsion of kidney stones.

May PC, Bailey MR, Harper JD.

Curr Opin Urol. 2016 May;26(3):264-70. doi: 10.1097/MOU.0000000000000276. Review.

14.

Preparation and biological evaluation of conformationally constrained BACE1 inhibitors.

Winneroski LL, Schiffler MA, Erickson JA, May PC, Monk SA, Timm DE, Audia JE, Beck JP, Boggs LN, Borders AR, Boyer RD, Brier RA, Hudziak KJ, Klimkowski VJ, Garcia Losada P, Mathes BM, Stout SL, Watson BM, Mergott DJ.

Bioorg Med Chem. 2015 Jul 1;23(13):3260-8. doi: 10.1016/j.bmc.2015.04.062. Epub 2015 May 6.

PMID:
26001341
15.

The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans.

May PC, Willis BA, Lowe SL, Dean RA, Monk SA, Cocke PJ, Audia JE, Boggs LN, Borders AR, Brier RA, Calligaro DO, Day TA, Ereshefsky L, Erickson JA, Gevorkyan H, Gonzales CR, James DE, Jhee SS, Komjathy SF, Li L, Lindstrom TD, Mathes BM, Martényi F, Sheehan SM, Stout SL, Timm DE, Vaught GM, Watson BM, Winneroski LL, Yang Z, Mergott DJ.

J Neurosci. 2015 Jan 21;35(3):1199-210. doi: 10.1523/JNEUROSCI.4129-14.2015.

16.

β-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid precursor protein cleavage.

Portelius E, Dean RA, Andreasson U, Mattsson N, Westerlund A, Olsson M, Demattos RB, Racke MM, Zetterberg H, May PC, Blennow K.

Alzheimers Res Ther. 2014 Nov 17;6(5-8):75. doi: 10.1186/s13195-014-0075-0. eCollection 2014.

17.

Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings.

Henley DB, Sundell KL, Sethuraman G, Dowsett SA, May PC.

Curr Med Res Opin. 2014 Oct;30(10):2021-32. doi: 10.1185/03007995.2014.939167. Epub 2014 Jul 14.

PMID:
24983746
18.

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D.

J Clin Invest. 2013 Oct;123(10):4144-57. doi: 10.1172/JCI68951. Epub 2013 Sep 3.

19.

Double minutes with MYC amplification in a patient with chronic myelomonocytic leukaemia transformed into acute myeloid leukaemia.

Deplano S, May PC, Pavlů J.

Br J Haematol. 2013 Sep;162(6):720. doi: 10.1111/bjh.12482. Epub 2013 Jul 17. No abstract available.

PMID:
23862742
20.

Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma.

Chaidos A, Barnes CP, Cowan G, May PC, Melo V, Hatjiharissi E, Papaioannou M, Harrington H, Doolittle H, Terpos E, Dimopoulos M, Abdalla S, Yarranton H, Naresh K, Foroni L, Reid A, Rahemtulla A, Stumpf M, Roberts I, Karadimitris A.

Blood. 2013 Jan 10;121(2):318-28. doi: 10.1182/blood-2012-06-436220. Epub 2012 Nov 20.

PMID:
23169779
21.

Observation of Auer rods in crushed cells helps in the diagnosis of acute promyelocytic leukemia.

Osman Ahmed S, Deplano S, May PC, Bain BJ.

Am J Hematol. 2013 Mar;88(3):236. doi: 10.1002/ajh.23320. Epub 2012 Aug 22. No abstract available.

22.

Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease.

Portelius E, Zetterberg H, Dean RA, Marcil A, Bourgeois P, Nutu M, Andreasson U, Siemers E, Mawuenyega KG, Sigurdson WC, May PC, Paul SM, Holtzman DM, Blennow K, Bateman RJ.

J Alzheimers Dis. 2012;31(2):335-41. doi: 10.3233/JAD-2012-120508.

23.

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.

May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, Watson BM, Stout SL, Timm DE, Smith Labell E, Gonzales CR, Nakano M, Jhee SS, Yen M, Ereshefsky L, Lindstrom TD, Calligaro DO, Cocke PJ, Greg Hall D, Friedrich S, Citron M, Audia JE.

J Neurosci. 2011 Nov 16;31(46):16507-16. doi: 10.1523/JNEUROSCI.3647-11.2011.

24.

Unexpected pancytopenia following treatment of acute lymphoblastic leukemia.

Innes A, May PC, Pavlů J, Bain BJ.

Am J Hematol. 2012 Apr;87(4):412. doi: 10.1002/ajh.22159. Epub 2011 Sep 26. No abstract available.

25.

Bone marrow trephine biopsy findings in acute promyelocytic leukemia.

Al-Shieban S, Liu C, Fishlock K, May PC, Pavlu J, Naresh KN.

Am J Hematol. 2012 Jan;87(1):109-10. doi: 10.1002/ajh.22127. Epub 2011 Sep 8. No abstract available.

26.

Bone marrow trephine biopsy findings in myeloma with small-lymphoid cells and CCND1 translocation.

Abdalla S, May PC, Garimberti E, Naresh KN.

Am J Hematol. 2011 Dec;86(12):1038. doi: 10.1002/ajh.22128. Epub 2011 Sep 2. No abstract available.

27.

Validation of ELISA methods for quantification of total tau and phosporylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies.

Lachno DR, Romeo MJ, Siemers ER, Vanderstichele H, Coart E, Konrad RJ, Zajac JJ, Talbot JA, Jensen HF, Sethuraman G, Demattos RB, May PC, Dean RA.

J Alzheimers Dis. 2011;26(3):531-41. doi: 10.3233/JAD-2011-110296.

PMID:
21694458
28.

Bone marrow trephine biopsy findings in B acute lymphoblastic leukaemia of early precursor (Pro-B) subtype.

Schwarb H, May PC, Apperley J, Naresh KN.

Am J Hematol. 2011 Feb;86(2):195-6. doi: 10.1002/ajh.21945. No abstract available.

29.

Inhibition of beta-secretase in vivo via antibody binding to unique loops (D and F) of BACE1.

Zhou L, Chávez-Gutiérrez L, Bockstael K, Sannerud R, Annaert W, May PC, Karran E, De Strooper B.

J Biol Chem. 2011 Mar 11;286(10):8677-87. doi: 10.1074/jbc.M110.194860. Epub 2011 Jan 5.

30.

T cell lymphoblastic leukaemia/lymphoma associated with a microenvironment of thymic asteroid B cells in the bone marrow.

Naresh KN, May PC, Reid AG, Marks AJ, Macdonald D, Kanfer E.

Histopathology. 2010 Oct;57(4):549-54. doi: 10.1111/j.1365-2559.2010.03663.x. Epub 2010 Sep 28.

PMID:
20875071
31.

EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.

Daghistani M, Marin D, Khorashad JS, Wang L, May PC, Paliompeis C, Milojkovic D, De Melo VA, Gerrard G, Goldman JM, Apperley JF, Clark RE, Foroni L, Reid AG.

Blood. 2010 Dec 23;116(26):6014-7. doi: 10.1182/blood-2010-01-264234. Epub 2010 Sep 20.

PMID:
20855863
32.

hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.

Bazeos A, Marin D, Reid AG, Gerrard G, Milojkovic D, May PC, de Lavallade H, Garland P, Rezvani K, Apperley JF, Goldman JM, Foroni L, Khorashad JS.

Leukemia. 2010 Jun;24(6):1243-5. doi: 10.1038/leu.2010.86. Epub 2010 May 6. No abstract available.

PMID:
20445576
33.

Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials.

Siemers E, DeMattos RB, May PC, Dean RA.

Biomark Med. 2010 Feb;4(1):81-9. Review.

PMID:
20387304
34.

Detection of cryptic and variant IGH-MYC rearrangements in high-grade non-Hodgkin's lymphoma by fluorescence in situ hybridization: implications for cytogenetic testing.

May PC, Foot N, Dunn R, Geoghegan H, Neat MJ.

Cancer Genet Cytogenet. 2010 Apr 1;198(1):71-5. doi: 10.1016/j.cancergencyto.2009.12.010.

PMID:
20303018
35.

Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.

Henley DB, May PC, Dean RA, Siemers ER.

Expert Opin Pharmacother. 2009 Jul;10(10):1657-64. doi: 10.1517/14656560903044982. Review.

PMID:
19527190
36.

A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.

Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM.

Ann Neurol. 2009 Jul;66(1):48-54. doi: 10.1002/ana.21623.

38.

gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease.

Serneels L, Van Biervliet J, Craessaerts K, Dejaegere T, Horré K, Van Houtvin T, Esselmann H, Paul S, Schäfer MK, Berezovska O, Hyman BT, Sprangers B, Sciot R, Moons L, Jucker M, Yang Z, May PC, Karran E, Wiltfang J, D'Hooge R, De Strooper B.

Science. 2009 May 1;324(5927):639-42. doi: 10.1126/science.1171176. Epub 2009 Mar 19.

39.

Partnership between academia and industry for drug discovery in Alzheimer's disease.

Ivinson AJ, Lane R, May PC, Hosford DA, Carrillo MC, Siemers ER.

Alzheimers Dement. 2008 Mar;4(2):80-8. doi: 10.1016/j.jalz.2008.02.004. Erratum in: Alzheimers Dement. 2008 May;4(3):230-1.

PMID:
18631952
40.

An Evaluation of the Effectiveness of a Semi-automatic Metaphase Locating and On-screen Karyotyping System.

May PC, Ogilvie CM, Mohammed S, Docherty Z, Hall RP.

J Assoc Genet Technol. 2008;34(4):177-87.

PMID:
20081315
41.

Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase.

Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, May PC.

Clin Neuropharmacol. 2007 Nov-Dec;30(6):317-25.

PMID:
18090456
42.

New pathways in drug discovery for Alzheimer's disease.

Siemers ER, Dean RA, Demattos R, May PC.

Curr Neurol Neurosci Rep. 2006 Sep;6(5):372-8. Review.

PMID:
16928346
43.

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.

Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, Knopman DS, Satterwhite J, Gonzales C, Dean RA, May PC.

Neurology. 2006 Feb 28;66(4):602-4.

PMID:
16505324
44.

Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo.

Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM.

Neuron. 2005 Dec 22;48(6):913-22.

45.

Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers.

Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, Ness D, May PC.

Clin Neuropharmacol. 2005 May-Jun;28(3):126-32.

PMID:
15965311
46.

Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB.

J Neurosci. 2005 Jan 19;25(3):629-36.

47.

Biochemical and kinetic characterization of BACE1: investigation into the putative species-specificity for beta- and beta'-cleavage sites by human and murine BACE1.

Yang HC, Chai X, Mosior M, Kohn W, Boggs LN, Erickson JA, McClure DB, Yeh WK, Zhang L, Gonzalez-DeWhitt P, Mayer JP, Martin JA, Hu J, Chen SH, Bueno AB, Little SP, McCarthy JR, May PC.

J Neurochem. 2004 Dec;91(6):1249-59.

48.

ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo.

DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW, Harmony JA, Aronow BJ, Bales KR, Paul SM, Holtzman DM.

Neuron. 2004 Jan 22;41(2):193-202.

49.

A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes.

Liang Y, Lin S, Beyer TP, Zhang Y, Wu X, Bales KR, DeMattos RB, May PC, Li SD, Jiang XC, Eacho PI, Cao G, Paul SM.

J Neurochem. 2004 Feb;88(3):623-34.

50.

Design and synthesis of statine-containing BACE inhibitors.

Hu J, Cwi CL, Smiley DL, Timm D, Erickson JA, McGee JE, Yang HC, Mendel D, May PC, Shapiro M, McCarthy JR.

Bioorg Med Chem Lett. 2003 Dec 15;13(24):4335-9.

PMID:
14643321

Supplemental Content

Support Center